Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCL004
MIFTS: 44

B-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for B-Cell Non-Hodgkin Lymphoma

About this section

MalaCards integrated aliases for B-Cell Non-Hodgkin Lymphoma:

Name: B-Cell Non-Hodgkin Lymphoma 58 29 6
B-Cell Non-Hodgkins Lymphoma 17
B-Cell Nhl 58

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare haematological diseases


External Ids:

Orphanet 58 ORPHA171915
Sources

Summaries for B-Cell Non-Hodgkin Lymphoma

About this section
MalaCards based summary : B-Cell Non-Hodgkin Lymphoma, also known as b-cell non-hodgkins lymphoma, is related to mantle cell lymphoma and lymphoma. An important gene associated with B-Cell Non-Hodgkin Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Gene Expression and Apoptotic Pathways in Synovial Fibroblasts. The drugs Ketamine and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Sources

Related Diseases for B-Cell Non-Hodgkin Lymphoma

About this section

Diseases in the B-Cell Non-Hodgkin Lymphoma family:

T-Cell Non-Hodgkin Lymphoma

Diseases related to B-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 mantle cell lymphoma 32.1 MS4A1 BCL6 ATM
2 lymphoma 31.3 MS4A1 BCL7A BCL6 ATM
3 cll/sll 30.6 BCL6 ATM
4 burkitt lymphoma 30.5 MS4A1 BCL7A BCL6 ATM
5 plasmablastic lymphoma 30.1 MS4A1 BCL6
6 leukemia, chronic lymphocytic 2 30.0 MS4A1 ATM
7 leukemia, acute myeloid 27.0 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
8 aggressive b-cell non-hodgkin lymphoma 12.9
9 indolent b-cell non-hodgkin lymphoma 12.9
10 lymphoma, hodgkin, classic 11.4
11 lymphoma, non-hodgkin, familial 11.4
12 b-cell lymphoma 11.2
13 diffuse large b-cell lymphoma 11.1
14 follicular lymphoma 11.0
15 neutropenia 11.0
16 leukemia, chronic lymphocytic 10.8
17 marginal zone b-cell lymphoma 10.8
18 hepatitis c virus 10.6
19 hepatitis c 10.6
20 leukemia, acute lymphoblastic 10.5
21 lymphoplasmacytic lymphoma 10.5
22 cryoglobulinemia 10.5
23 autoimmune disease 10.4
24 cryoglobulinemia, familial mixed 10.4
25 myeloma, multiple 10.4
26 myelodysplastic syndrome 10.4
27 thrombocytopenia 10.4
28 lymphopenia 10.4
29 severe combined immunodeficiency 10.4
30 splenic marginal zone lymphoma 10.4
31 primary mediastinal b-cell lymphoma 10.4
32 hairy cell leukemia 10.4
33 lymphosarcoma 10.4
34 splenomegaly 10.4
35 lymphoma, mucosa-associated lymphoid type 10.3
36 leukemia, acute lymphoblastic 3 10.3
37 exanthem 10.3
38 nodal marginal zone lymphoma 10.3
39 agammaglobulinemia 10.3
40 peripheral nervous system disease 10.3
41 vasculitis 10.3
42 neuropathy 10.3
43 indolent b cell lymphoma 10.3
44 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
45 paroxysmal nocturnal hemoglobinuria 10.2
46 lymphoproliferative syndrome 10.2
47 lymphoblastic lymphoma 10.2
48 relapsed/refractory diffuse large b-cell lymphoma 10.2
49 common variable immunodeficiency 10.2
50 leukemia 10.2

Graphical network of the top 20 diseases related to B-Cell Non-Hodgkin Lymphoma:



Diseases related to B-Cell Non-Hodgkin Lymphoma
Sources

Symptoms & Phenotypes for B-Cell Non-Hodgkin Lymphoma

About this section

GenomeRNAi Phenotypes related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 10.17 H4C13
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.17 H4C13
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 10.17 H4C11 H4C12
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-13 10.17 H4C11 H4C12
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.17 H4C13
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.17 H4C13
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 10.17 H4C13
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 10.17 H4C11 H4C12
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.17 H4C11 H4C12
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-4 10.17 H4C11 H4C12
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-41 10.17 H4C11 H4C12
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 10.17 H4C11 H4C12
13 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.72 ATM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.72 ATM H4C11 H4C12
15 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.72 ATM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.72 H4C11 H4C12
17 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.72 ATM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.72 ATM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.72 ATM
20 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.72 ATM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.72 ATM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-160 9.72 ATM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.72 H4C11 H4C12
24 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.72 ATM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.72 H4C11 H4C12
26 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.72 ATM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-71 9.72 H4C11 H4C12
28 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.72 ATM
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 ATM
30 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.72 H4C11 H4C12
Sources

Drugs & Therapeutics for B-Cell Non-Hodgkin Lymphoma

About this section

Drugs for B-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Carmustine Approved, Investigational Phase 3 154-93-8 2578
3
Pixantrone Approved, Investigational Phase 3 144510-96-3
4
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
5
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
6
Allopurinol Approved Phase 3 315-30-0 2094
7
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
8
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
9
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
10
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
12
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
13 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
14
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
15
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
16
Idarubicin Approved Phase 3 58957-92-9 42890
17
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
18
Lenalidomide Approved Phase 3 191732-72-6 216326
19
ofatumumab Approved Phase 3 679818-59-8 6918251
20
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
22 Molgramostim Investigational Phase 3 99283-10-0
23
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
24 Anesthetics, General Phase 3
25 Anesthetics, Intravenous Phase 3
26 Excitatory Amino Acid Antagonists Phase 3
27 Anesthetics, Dissociative Phase 3
28 Folic Acid Antagonists Phase 3
29 Antioxidants Phase 3
30 Calcium, Dietary Phase 3
31 Analgesics, Opioid Phase 3
32 Vitamin B Complex Phase 2, Phase 3
33 Folate Phase 2, Phase 3
34 Vitamin B9 Phase 2, Phase 3
35 Trace Elements Phase 2, Phase 3
36 Nutrients Phase 2, Phase 3
37 Micronutrients Phase 2, Phase 3
38 Vitamins Phase 2, Phase 3
39 Methylprednisolone Acetate Phase 3
40 Adjuvants, Immunologic Phase 2, Phase 3
41 Antidotes Phase 2, Phase 3
42 Hematinics Phase 2, Phase 3
43 Angiogenesis Inhibitors Phase 3
44 Immunoglobulins Phase 3
45 Antibodies Phase 3
46 Antibodies, Monoclonal Phase 3
47 Alkylating Agents Phase 3
48 Bendamustine Hydrochloride Phase 3
49
Calcium Nutraceutical Phase 3 7440-70-2 271
50
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5

Interventional clinical trials:

(show top 50) (show all 301)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
3 A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL) Completed NCT02747043 Phase 3 ABP 798;Rituximab
4 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
5 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
6 A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY) Completed NCT00012051 Phase 3 carmustine;cisplatin;cytarabine;dexamethasone;etoposide;ifosfamide;melphalan;methotrexate
7 A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma Completed NCT00000658 Phase 3 Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Sargramostim;Dexamethasone
8 A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
9 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
10 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
11 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
12 Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China Recruiting NCT02405676 Phase 2, Phase 3 Prednisone,Vincristine, Cyclophosphamide;Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone;Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone;Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone;Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone;Rituximab
13 Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA) Recruiting NCT03570892 Phase 3 Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy;Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
14 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
15 B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents Recruiting NCT03206671 Phase 3 Rituximab window;Additional doses of Rituximab;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin hydrochloride;Vindesine Sulfate;Etoposide;Ifosfamide;Methotrexate;Prednisolone;Vincristine
16 A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma Recruiting NCT02703272 Phase 3 Ibrutinib;Rituximab;Ifosfamide;Carboplatin;Etoposide;Vincristine;Idarubicin;Dexamethasone
17 A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM). Recruiting NCT03575351 Phase 3 Standard of Care
18 Mature B-Cell Lymphoma And Leukemia Study III Recruiting NCT01046825 Phase 2, Phase 3 COPAD;COP, COPD M3, CYM;COP, COPADM8, CYVE
19 A Prospective, Randomized, Open-label, Multi-center Study of Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma: Wuhan University Cancer Center -NHL02 Trial Recruiting NCT02438501 Phase 3
20 Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial Active, not recruiting NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
21 A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma Active, not recruiting NCT01996865 Phase 3 Lenalidomide;Rituximab
22 A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab Terminated NCT01289223 Phase 3 Bendamustine IV
23 Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy Terminated NCT01200589 Phase 3
24 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL Terminated NCT02366663 Phase 3 Carmustine;Etoposide;Cytarabine;Melphalan
25 Randomized Open Label of Ofatumumab and Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment Terminated NCT01077518 Phase 3 Ofatumumab;Bendamustine infusion;Ofatumumab and Bendamustine infusions (Arm A);Bendamustine infusion (Arm B)
26 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
27 Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation. Unknown status NCT00385125 Phase 2 Bendamustine;Rituximab
28 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life Unknown status NCT00911183 Phase 2 cyclophosphamide;liposome-encapsulated doxorubicin citrate;prednisone;vincristine sulfate
29 Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
30 Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL Unknown status NCT01516567 Phase 2 Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
31 A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk) Unknown status NCT00974792 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
32 Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-Line CHOP Unknown status NCT00022932 Phase 2 Iodine-131 Anti-B1 Antibody
33 Pilot Study of Autologous T Lymphocytes With Antibody-Dependent Cell Cytotoxicity in Patients With CD20-Positive B-Cell Malignancies Unknown status NCT02315118 Phase 1, Phase 2 T-cell therapy + Rituximab + IL-2
34 Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status Unknown status NCT00333008 Phase 2 Doxil;Cyclophosphamide;Vincristine;Prednisone;Rituximab;Pegfilgrastim
35 An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL) Completed NCT02151903 Phase 1, Phase 2 DI-Leu16-IL2
36 A Phase II Multicenter Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non-Hodgkins Lymphoma. Completed NCT00211276 Phase 2 ONTAK (denileukin diftitox)
37 A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma Completed NCT00166439 Phase 2 Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
38 A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Completed NCT01030536 Phase 1, Phase 2 CAT-8015 20 mcg/kg;CAT-8015 30 mcg/kg;CAT-8015 40 mcg/kg;CAT-8015 50 mcg/kg;CAT-8015 60 mcg/kg
39 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
40 A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL) Completed NCT01874288 Phase 1, Phase 2 0.5 mg/m2 DI-Leu16-IL2;1.0 mg/m2 DI-Leu16-IL2;2.0 mg/m2 DI-Leu16-IL2;4.0 mg/m2 DI-Leu16-IL2;6.0 mg/m2 DI-Leu16-IL2;8.0 mg/m2 DI-Leu16-IL2;10.0 mg/m2 DI-Leu16-IL2;50mg/m2 Rituximab
41 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma Completed NCT02253992 Phase 1, Phase 2
42 A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Completed NCT01281917 Phase 2 Velcade;Temsirolimus
43 An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy Completed NCT01647971 Phase 1, Phase 2 Ublituximab
44 A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma Completed NCT02910063 Phase 2 Blinatumomab
45 A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00765245 Phase 2 Lenalidomide;Lenalidomide;Rituximab
46 Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma Completed NCT00764517 Phase 2 Cladribine;Vorinostat
47 Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD) Completed NCT01058239 Phase 2 bortezomib;rituximab
48 Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL) Completed NCT02141451 Phase 1, Phase 2 Rituximab;INCB7839
49 Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day Intervals (CHOP-14), Both With or Without the Monoclonal Anti-CD20 Antibody Rituximab Completed NCT00726700 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
50 A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Completed NCT00229619 Phase 2 Rituximab

Search NIH Clinical Center for B-Cell Non-Hodgkin Lymphoma

Sources

Genetic Tests for B-Cell Non-Hodgkin Lymphoma

About this section

Genetic tests related to B-Cell Non-Hodgkin Lymphoma:

# Genetic test Affiliating Genes
1 B-Cell Non-Hodgkin Lymphoma 29
Sources

Anatomical Context for B-Cell Non-Hodgkin Lymphoma

About this section

MalaCards organs/tissues related to B-Cell Non-Hodgkin Lymphoma:

40
B Cells, T Cells, Bone, Nk Cells, Bone Marrow, Liver, Breast
Sources

Publications for B-Cell Non-Hodgkin Lymphoma

About this section

Articles related to B-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 1274)
# Title Authors PMID Year
1
Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. 6
9288106 1997
2
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. 61
31868632 2020
3
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma. 61
32243637 2020
4
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. 61
32578153 2020
5
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 61
32546071 2020
6
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. 61
32141616 2020
7
Erythrocyte Levels of Cadmium and Lead and Risk of B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma. 61
32506449 2020
8
Primary dural lymphomas: Clinical presentation, management, and outcome. 61
32176324 2020
9
Diffuse large B-cell lymphoma relapse presenting as extensive neurolymphomatosis. 61
32401669 2020
10
Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. 61
32535708 2020
11
Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan. 61
32519171 2020
12
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. 61
32222808 2020
13
Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma. 61
32444689 2020
14
B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. 61
32451774 2020
15
Clinicopathologic Characterization of Children With B-Cell Non-Hodgkin Lymphoma Over 10 Years at a Tertiary Center in Cape Town, South Africa. 61
32332383 2020
16
Burkitt lymphoma presenting with fever of unknown origin and isolated hypoglossal nerve palsy. 61
31425376 2020
17
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. 61
31836849 2020
18
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 61
32474843 2020
19
Management of children and adolescents with gray zone lymphoma: A case series. 61
32037692 2020
20
Novel agents for mantle cell lymphoma: molecular rational and clinical data. 61
32321318 2020
21
Serological hepatitis B virus (HBV) activity in patients with HBV infection and B-cell non-Hodgkin's lymphoma. 61
31961011 2020
22
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. 61
31997425 2020
23
Management of Older Adults with Mantle Cell Lymphoma. 61
32367497 2020
24
The BiTE (Bispecific T-Cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. 61
32401342 2020
25
Occult primary cardiac lymphomas causing unexpected/sudden death or acute heart failure. 61
32372222 2020
26
Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy. 61
32559556 2020
27
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. 61
31296574 2020
28
Reverse pseudohyperkalemia and pseudohyponatremia in a patient with B-cell non-Hodgkin lymphoma. 61
32014484 2020
29
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result. 61
31838764 2020
30
Aggressive B-Cell Lymphoma Involving the Appendix and Bilateral Ovaries in an 11-Year-Old Girl. 61
32304857 2020
31
Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not? 61
32304874 2020
32
25-Hydroxy vitamin D deficiency predicts inferior prognosis in mantle cell lymphoma. 61
31915915 2020
33
Immunological microenvironment gene expression in patients with diffuse large B cell non Hodgkin lymphoma. 61
32025577 2020
34
Clinical Utility of Radiologic Disease Reassessment in the Management of Pediatric B-Cell Non-Hodgkin Lymphoma. 61
32218099 2020
35
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 61
32172489 2020
36
Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib. 61
31932250 2020
37
Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma. 61
32120334 2020
38
Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing. 61
32160292 2020
39
Practical Approach to the Histologic Diagnosis of Gastrointestinal Lymphomas Through the First-line Marker Battery of CD20, CD3, CD30, and Epstein-Barr Virus-encoded RNAs. 61
31913182 2020
40
Emerging Role of Podocalyxin in the Progression of Mature B-Cell Non-Hodgkin Lymphoma. 61
32046309 2020
41
Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. 61
31846632 2020
42
Antiproliferative and proapoptotic effects of Inula viscosa extract on Burkitt lymphoma cell line. 61
32013807 2020
43
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. 61
32102267 2020
44
Diffused mixed B-cell non-Hodgkin lymphoma of mandible. 61
32189910 2020
45
Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma. 61
31909406 2020
46
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). 61
32041862 2020
47
Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. 61
31902733 2020
48
MicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway. 61
32055277 2020
49
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. 61
31677848 2020
50
C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases. 61
31892985 2020
Sources

Variations for B-Cell Non-Hodgkin Lymphoma

About this section

ClinVar genetic disease variations for B-Cell Non-Hodgkin Lymphoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_000051.3(ATM):c.3118A>G (p.Met1040Val)SNV Benign/Likely benign 3027 rs3092857 11:108143299-108143299 11:108272572-108272572
Sources

Expression for B-Cell Non-Hodgkin Lymphoma

About this section
Search GEO for disease gene expression data for B-Cell Non-Hodgkin Lymphoma.
Sources

Pathways for B-Cell Non-Hodgkin Lymphoma

About this section

Pathways related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Gene Expression 65
Show member pathways
 13.6 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
2
Apoptotic Pathways in Synovial Fibroblasts 63
Show member pathways
 13.55 H4C14 H4C13 H4C12 H4C11 H4C1 ATM
3
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 65
Show member pathways
 13.49 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
4
Developmental Biology 65
Show member pathways
 13.27 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
5
Cell Cycle, Mitotic 65
Show member pathways
 13.26 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
6
DNA Double-Strand Break Repair 65
Show member pathways
 13.06 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
7
Cellular Senescence (REACTOME) 65
Show member pathways
 12.99 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
8
Signaling by Rho GTPases 65
Show member pathways
 12.88 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
9
Chromatin organization 65
Show member pathways
 12.86 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
10
RNA Polymerase II Transcription Initiation And Promoter Clearance 65
Show member pathways
 12.83 H4C14 H4C13 H4C12 H4C11 H4C1
11
Signaling by Wnt 65
Show member pathways
 12.76 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
12
Mitotic Prophase 65
Show member pathways
 12.58 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
13
Cell Cycle Checkpoints 65
Show member pathways
 12.52 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
14
Chromosome Maintenance 65
Show member pathways
 12.46 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
15
Meiosis 65
Show member pathways
 12.26 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
16
Viral carcinogenesis 36
12.22 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
17
Development NOTCH1-mediated pathway for NF-KB activity modulation 22
Show member pathways
 12.08 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
18
DNA Double Strand Break Response 65
Show member pathways
 12.06 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
19
PKMTs methylate histone lysines 65
Show member pathways
 11.95 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
20
DNA Damage/Telomere Stress Induced Senescence 65
Show member pathways
 11.85 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
21
Signaling events mediated by HDAC Class III 1
10.69 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
Sources

GO Terms for B-Cell Non-Hodgkin Lymphoma

About this section

Cellular components related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10.11 MS4A1 H4C14 H4C13 H4C12 H4C11 H4C1
2 extracellular exosome GO:0070062 10.03 MS4A1 LCP1 H4C14 H4C13 H4C12 H4C11
3 extracellular region GO:0005576 9.95 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
4 protein-containing complex GO:0032991 9.88 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
5 chromosome GO:0005694 9.85 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
6 host cell nucleus GO:0042025 9.8 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
7 nucleosome GO:0000786 9.73 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
8 nuclear chromosome GO:0000228 9.63 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
9 nuclear chromosome, telomeric region GO:0000784 9.5 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
10 nuclear nucleosome GO:0000788 9.1 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16

Biological processes related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 10.01 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
2 nucleosome assembly GO:0006334 10 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
3 regulation of gene silencing by miRNA GO:0060964 9.99 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
4 regulation of megakaryocyte differentiation GO:0045652 9.97 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
5 negative regulation of gene expression, epigenetic GO:0045814 9.95 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
6 CENP-A containing nucleosome assembly GO:0034080 9.93 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
7 DNA-templated transcription, initiation GO:0006352 9.91 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
8 chromatin silencing at rDNA GO:0000183 9.88 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
9 DNA replication-dependent nucleosome assembly GO:0006335 9.85 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
10 telomere organization GO:0032200 9.8 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
11 telomere capping GO:0016233 9.73 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
12 DNA replication-independent nucleosome assembly GO:0006336 9.63 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
13 double-strand break repair via nonhomologous end joining GO:0006303 9.5 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
14 negative regulation of megakaryocyte differentiation GO:0045653 9.1 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16

Molecular functions related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.06 MS4A1 LCP1 H4C14 H4C13 H4C12 H4C11
2 DNA binding GO:0003677 9.76 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
3 RNA binding GO:0003723 9.73 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
4 protein heterodimerization activity GO:0046982 9.43 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
5 protein domain specific binding GO:0019904 9.1 H4C14 H4C13 H4C12 H4C11 H4C1 H4-16
Sources

Sources for B-Cell Non-Hodgkin Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....